Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.
BACKGROUND Fruquintinib has demonstrated survival benefits in patients with previously treated metastatic colorectal cancer (mCRC) in phase III trials. However, real-world data in Japanese patients remain limited. This study evaluated the effectiveness and safety of fruquintinib in routine clinical practice. METHODS...